RU2016108598A - Функционализированные полипептиды - Google Patents

Функционализированные полипептиды Download PDF

Info

Publication number
RU2016108598A
RU2016108598A RU2016108598A RU2016108598A RU2016108598A RU 2016108598 A RU2016108598 A RU 2016108598A RU 2016108598 A RU2016108598 A RU 2016108598A RU 2016108598 A RU2016108598 A RU 2016108598A RU 2016108598 A RU2016108598 A RU 2016108598A
Authority
RU
Russia
Prior art keywords
linker
amino acid
seq
scfv
sequence shown
Prior art date
Application number
RU2016108598A
Other languages
English (en)
Inventor
Дэвид УРЕХ
Original Assignee
ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи filed Critical ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи
Publication of RU2016108598A publication Critical patent/RU2016108598A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1062—Isolating an individual clone by screening libraries mRNA-Display, e.g. polypeptide and encoding template are connected covalently
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Claims (10)

1. Способ модификации фармакокинетических (PK) свойств scFv, включающий применение аминокислотного линкера, содержащего последовательность аминокислот, представленную в SEQ ID No.2, который соединяет домены VH и VL scFv, при этом модификатор PK способен связываться с линкером.
2. Способ по п.1, где линкер включает последовательность аминокислот, представленную в SEQ ID No.3.
3. Способ по п.1, где модификатор РК представляет собой сывороточный альбумин, гиалуроновую кислоту, коллаген типа II, Fc-области антител, рецепторы антител Fc, муцины, интегрины, белки плотного контакта, трансферрин или факторы комплемента.
4. Способ по п.1, где линкер включает последовательность аминокислот, представленную в SEQ ID No.4.
5. Способ по п.1, где scFv включает последовательность аминокислот, представленную в SEQ ID No.6 или 8.
6. Способ по любому из пп.1-5, где
по меньшей мере один цистеиновый остаток в линкере является ковалентно связанным с функциональным фрагментом; или
два цистеиновых остатка в линкере являются ковалентно связанными с функциональным фрагментом.
7. Способ по п.6, где функциональный фрагмент представляет собой ПЭГ, молекулы углеводов или HES.
8. Фармацевтическая композиция, содержащая терапевтически эффективное количество scFv, полученного в соответствии со способом по п.1, и фармацевтически приемлемый носитель.
RU2016108598A 2008-06-30 2009-06-30 Функционализированные полипептиды RU2016108598A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7677508P 2008-06-30 2008-06-30
US61/076,775 2008-06-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2011103168/10A Division RU2582244C2 (ru) 2008-06-30 2009-06-30 Функционализированные полипептиды

Publications (1)

Publication Number Publication Date
RU2016108598A true RU2016108598A (ru) 2018-11-23

Family

ID=41139486

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2016108598A RU2016108598A (ru) 2008-06-30 2009-06-30 Функционализированные полипептиды
RU2011103168/10A RU2582244C2 (ru) 2008-06-30 2009-06-30 Функционализированные полипептиды

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2011103168/10A RU2582244C2 (ru) 2008-06-30 2009-06-30 Функционализированные полипептиды

Country Status (12)

Country Link
US (3) US8637022B2 (ru)
EP (2) EP2304033B1 (ru)
JP (3) JP5988580B2 (ru)
KR (2) KR101678925B1 (ru)
CN (2) CN105153300A (ru)
AU (1) AU2009270405B2 (ru)
BR (1) BRPI0915343A2 (ru)
CA (1) CA2729185A1 (ru)
MX (2) MX2011000006A (ru)
RU (2) RU2016108598A (ru)
WO (1) WO2010006454A2 (ru)
ZA (1) ZA201008596B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0915460A2 (pt) * 2008-07-10 2015-11-10 Esbatech Alcon Biomed Res Unit métodos e composições para a liberação intensificada de macromoléculas
US20100056766A1 (en) * 2008-08-27 2010-03-04 Abbott Laboratories Purification of biological conjugates by size exclusion chromatography
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
RU2018112861A (ru) 2011-10-20 2019-03-04 ИЭсБиЭйТЕК - Э НОВАРТИС КОМПАНИ ЭлЭлСи Стабильные антитела, связывающиеся с несколькими антигенами
CA2943445A1 (en) * 2014-03-26 2015-10-01 Cell Medica Switzerland Ag Binding members to tnf alpha
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
JOP20220035A1 (ar) 2019-08-15 2023-01-30 Janssen Biotech Inc مواد وطرق لتحسين أجزاء المتغير أحادي السلسلة

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB9225453D0 (en) * 1992-12-04 1993-01-27 Medical Res Council Binding proteins
US6699658B1 (en) * 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
ATE332368T1 (de) 1997-01-21 2006-07-15 Gen Hospital Corp Selektion von proteinen mittels rns-protein fusionen
US20050159343A1 (en) * 1999-03-26 2005-07-21 Board Of Regents, University Of Texas System Inhibitors of glycosaminoglycans
AU774650B2 (en) 1999-03-26 2004-07-01 University Of Texas System, The Modulators of polysaccharides and uses thereof
WO2001017515A1 (en) 1999-09-03 2001-03-15 School Of Pharmacy, University Of London Degradable polymers
US6803438B1 (en) 1999-09-08 2004-10-12 Polytherics Limited Uniform molecular weight polymers
ES2270893T3 (es) 1999-12-24 2007-04-16 Genentech, Inc. Procedimiento y composiciones para prolongar la vida media de compuestos bioactivos.
US20050287153A1 (en) * 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
AU2001250212A1 (en) * 2000-04-20 2001-11-07 Cangene Corporation Rhamm peptide conjugates
EP1377306A1 (en) * 2001-03-09 2004-01-07 Dyax Corp. Serum albumin binding moieties
US7083970B2 (en) 2001-04-19 2006-08-01 The Scripps Research Institute Methods and compositions for the production of orthogonal tRNA-aminoacyl tRNA synthetase pairs
GB0131112D0 (en) 2001-12-31 2002-02-13 Univ London Pharmacy Block copolymers
GB0209022D0 (en) 2002-04-19 2002-05-29 Imp College Innovations Ltd Compounds
JP2006508638A (ja) * 2002-05-22 2006-03-16 エスバテック・アーゲー 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
MXPA05006688A (es) 2002-12-19 2006-02-22 Nektar Therapeutics Al Corp Conjugados de polimero con una variante de cianovirina.
WO2005000902A1 (en) * 2003-06-30 2005-01-06 Mu-Hyeon Choe The dimer of chimeric recombinant binding domain-functional group fusion formed via disulfide-bond-bridge and the processes for producing the same
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
GB0400264D0 (en) 2004-01-07 2004-02-11 Polytherics Ltd Complexes
CN101018809B (zh) * 2004-07-16 2012-07-18 米克罗麦特股份公司 表达增强的多肽
US7521541B2 (en) 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
MX2007003320A (es) * 2004-09-24 2007-05-18 Amgen Inc Moleculas fc modificadas.
WO2006074236A2 (en) * 2005-01-06 2006-07-13 Aromatic Technologies, Inc. Reduced smoking wick and candle
US7723472B2 (en) * 2005-02-28 2010-05-25 The Regents Of The University Of California Extracellular matrix binding chimeric proteins and methods of use thereof
CN105153306B (zh) 2005-06-07 2020-12-11 艾斯巴技术-诺华有限责任公司 抑制TNFα的稳定和可溶的抗体
JP2009509535A (ja) * 2005-09-27 2009-03-12 アムニクス， インコーポレイテッド タンパク様薬剤およびその使用
NZ596865A (en) * 2006-06-12 2013-07-26 Emergent Product Dev Seattle Single-chain multivalent binding proteins with effector function
RU2438708C2 (ru) 2006-07-10 2012-01-10 Эсбатек, Эн Элкон Биомедикал Рисёрч Юнит Ллк ScFv-АНТИТЕЛА, КОТОРЫЕ ПРОХОДЯТ ЧЕРЕЗ ЭПИТЕЛИАЛЬНЫЙ И/ИЛИ ЭНДОТЕЛИАЛЬНЫЙ СЛОИ
MX2009013327A (es) 2007-06-25 2010-06-02 Esbatech An Alcon Biomedical R Ingenieria basada en secuencias y optimizacion de anticuerpos de cadena simple.
CN101849001B (zh) * 2007-06-25 2014-07-16 艾斯巴技术-诺华有限责任公司 修饰抗体的方法和具有改善的功能性质的修饰抗体
KR102095257B1 (ko) * 2008-06-25 2020-04-01 노바르티스 아게 Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체

Also Published As

Publication number Publication date
CN102089431A (zh) 2011-06-08
KR20160046927A (ko) 2016-04-29
EP3130603A1 (en) 2017-02-15
US20160354479A1 (en) 2016-12-08
JP2016147909A (ja) 2016-08-18
EP2304033B1 (en) 2016-09-07
RU2011103168A (ru) 2012-08-10
US20110200594A1 (en) 2011-08-18
EP2304033A2 (en) 2011-04-06
US8637022B2 (en) 2014-01-28
JP2014111670A (ja) 2014-06-19
JP2011526145A (ja) 2011-10-06
KR20110039274A (ko) 2011-04-15
AU2009270405A1 (en) 2010-01-21
MX2011000006A (es) 2011-08-03
US9371525B2 (en) 2016-06-21
RU2582244C2 (ru) 2016-04-20
ZA201008596B (en) 2012-02-29
BRPI0915343A2 (pt) 2015-10-27
CN105153300A (zh) 2015-12-16
JP5988580B2 (ja) 2016-09-07
WO2010006454A3 (en) 2010-03-25
KR101678925B1 (ko) 2016-11-24
MX344076B (es) 2016-12-05
AU2009270405B2 (en) 2014-06-05
US20140178386A1 (en) 2014-06-26
CA2729185A1 (en) 2010-01-21
KR101711472B1 (ko) 2017-03-02
WO2010006454A2 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
RU2016108598A (ru) Функционализированные полипептиды
JP2016000731A5 (ru)
HRP20140258T1 (hr) Bispecifiäśni proteini koji se vežu na antigene
JP2018533369A5 (ru)
AU2014314214B2 (en) Binding polypeptides having a mutated scaffold
JP2011501951A5 (ru)
JP2005539067A5 (ru)
NZ596865A (en) Single-chain multivalent binding proteins with effector function
JP5874118B2 (ja) ＩｇＡ結合性ペプチド及びそれによるＩｇＡの精製
JP2010524472A5 (ru)
WO2017158097A1 (en) Anti-tnfalpha-antibodies and functional fragments thereof
JP6328781B2 (ja) 抗体結合性ポリペプチド、抗体結合性融合ポリペプチドおよび吸着材料
CN111004329A (zh) 一种基于光亲和共价连接的蛋白质分子弱相互作用捕获磁珠及其制备方法和应用
JP2006524510A5 (ru)
Lindgren et al. A GLP‐1 receptor agonist conjugated to an albumin‐binding domain for extended half‐life
JP2017036294A (ja) 非ペプチドヒンジ部含有フレキシブル抗体様分子
Vikholm-Lundin et al. Cysteine-tagged chimeric avidin forms high binding capacity layers directly on gold
US10065988B2 (en) Peptoid affinity ligands
Lamboy et al. Phage wrapping with cationic polymers eliminates nonspecific binding between M13 phage and high p I target proteins
EP3004136B1 (en) Peptoid affinity ligands for the purification of antibodies or antibody fragments
Wade et al. Use of thiazolidine-mediated ligation for site specific biotinylation of mouse EGF for biosensor immobilisation
JP6103772B2 (ja) ＩｇＡ結合性ペプチド及びそれによるＩｇＡの精製
WO2021256524A1 (ja) 免疫原性低減型低分子抗体とその製造法
CN102216319A (zh) 使用包含特异性配体的亲和树脂的抗体纯化方法
JP2011132140A (ja) 固定化タンパク質

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20190311